Profile data is unavailable for this security.
About the company
Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers. The Company’s lead product candidate includes azenosertib (ZN-c3), which is a WEE1 inhibitor for advanced solid tumors and hematological malignancies. The Company is also developing a BCL-2 inhibitor, ZN-d5, for hematological malignancies and related disorders. ZN-d5 is being evaluated in combination with azenosertib in a Phase I/II dose escalation clinical trial in patients with R/R acute myeloid leukemia (AML) (ZN-d5-004C). The Company is also advancing its research on protein degraders and other undisclosed targets using its Integrated Discovery Engine.
- Revenue in USD (TTM)40.56m
- Net income in USD-218.90m
- Incorporated2017
- Employees168.00
- LocationZentalis Pharmaceuticals Inc1359 Broadway, Suite 801NEW YORK 10018United StatesUSA
- Phone+1 (212) 433-3791
- Fax+1 (302) 655-5049
- Websitehttps://www.zentalis.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Disc Medicine Inc | 0.00 | -80.60m | 789.11m | 74.00 | -- | 2.33 | -- | -- | -3.37 | -3.37 | 0.00 | 13.69 | 0.00 | -- | -- | 0.00 | -26.96 | -- | -28.13 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -63.22 | -- | -- | -- |
| Longboard Pharmaceuticals Inc | 0.00 | -57.95m | 797.43m | 50.00 | -- | 2.54 | -- | -- | -2.25 | -2.25 | 0.00 | 8.07 | 0.00 | -- | -- | 0.00 | -28.45 | -- | -29.73 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -23.84 | -- | -- | -- |
| Arcturus Therapeutics Holdings Inc | 124.53m | -107.30m | 821.42m | 180.00 | -- | 3.11 | -- | 6.60 | -4.02 | -4.02 | 4.66 | 9.81 | 0.2799 | -- | 2.08 | 691,811.10 | -24.12 | -19.66 | -31.37 | -24.90 | -- | -- | -86.16 | -77.55 | -- | -- | 0.00 | -- | -19.03 | 60.31 | -417.95 | -- | 14.44 | -- |
| Aurinia Pharmaceuticals Inc | 191.41m | -62.56m | 825.22m | 300.00 | -- | 2.31 | -- | 4.31 | -0.4363 | -0.4363 | 1.34 | 2.50 | 0.3953 | 0.6008 | 7.98 | 638,023.30 | -12.92 | -25.97 | -14.63 | -28.24 | 88.78 | -- | -32.69 | -137.64 | 5.05 | -- | 0.1843 | -- | 30.95 | 227.90 | 27.88 | -- | 57.11 | -- |
| Tango Therapeutics Inc | 37.23m | -111.65m | 832.33m | 140.00 | -- | 3.14 | -- | 22.36 | -1.11 | -1.11 | 0.3742 | 2.48 | 0.0919 | -- | -- | 265,942.80 | -27.57 | -- | -31.29 | -- | -- | -- | -299.88 | -- | -- | -- | 0.00 | -- | 46.93 | -- | 5.95 | -- | -- | -- |
| CARGO Therapeutics Inc | 0.00 | -98.15m | 840.13m | 116.00 | -- | 2.17 | -- | -- | -2.37 | -2.37 | 0.00 | 9.84 | -- | -- | -- | 0.00 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -139.67 | -- | -- | -- |
| Nuvation Bio Inc | 0.00 | -68.87m | 842.85m | 159.00 | -- | 1.26 | -- | -- | -0.3146 | -0.3146 | 0.00 | 2.71 | 0.00 | -- | -- | 0.00 | -10.84 | -16.27 | -11.09 | -16.65 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 27.25 | -- | -- | -- |
| Prime Medicine Inc | 591.00k | -204.50m | 845.00m | 234.00 | -- | 3.47 | -- | 1,429.79 | -2.17 | -2.17 | 0.0062 | 2.03 | 0.0019 | -- | -- | 2,525.64 | -65.09 | -- | -70.51 | -- | -- | -- | -34,601.86 | -- | -- | -- | 0.00 | -- | -- | -- | -39.52 | -- | -- | -- |
| Zentalis Pharmaceuticals Inc | 40.56m | -218.90m | 849.32m | 168.00 | -- | -- | -- | 20.94 | -3.36 | -3.36 | 0.5934 | -- | -- | -- | -- | 241,428.60 | -- | -47.40 | -- | -54.18 | -- | -- | -506.16 | -- | -- | -- | -- | -- | -- | -- | -23.39 | -- | 20.76 | -- |
| Evolus Inc | 219.70m | -60.00m | 857.76m | 279.00 | -- | 46.26 | -- | 3.90 | -1.05 | -1.05 | 3.82 | 0.2962 | 1.14 | 3.86 | 7.62 | 804,750.90 | -31.06 | -40.92 | -40.14 | -59.74 | 69.28 | 65.43 | -27.31 | -80.46 | 2.96 | -2.90 | 0.8674 | -- | 35.98 | -- | 17.10 | -- | 182.77 | -- |
| Immunome Inc | 12.68m | -232.03m | 863.55m | 55.00 | -- | 3.01 | -- | 68.09 | -5.49 | -5.49 | 0.4273 | 4.78 | 0.069 | -- | -- | 230,600.00 | -126.15 | -94.54 | -148.61 | -112.66 | -- | -- | -1,829.44 | -1,403.15 | -- | -- | 0.00 | -- | -- | -- | -184.68 | -- | 29.52 | -- |
| Relay Therapeutics Inc | 35.33m | -329.12m | 864.15m | 309.00 | -- | 1.15 | -- | 24.46 | -2.64 | -2.64 | 0.2841 | 5.64 | 0.0376 | -- | -- | 109,371.50 | -35.03 | -28.55 | -37.16 | -29.54 | -- | -- | -931.64 | -998.20 | -- | -- | 0.00 | -- | 1,749.82 | -- | -17.72 | -- | 19.59 | -- |
| ProKidney Corp | 0.00 | -35.30m | 878.14m | 163.00 | -- | -- | -- | -- | -0.567 | -0.567 | 0.00 | -17.79 | 0.00 | -- | -- | 0.00 | -30.32 | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.0004 | -- | -- | -- | 67.17 | -- | -- | -- |
| ARS Pharmaceuticals Inc | 10.00k | -49.70m | 881.75m | 24.00 | -- | 3.93 | -- | 88,174.68 | -0.5198 | -0.5198 | 0.0001 | 2.32 | 0.00004 | -- | -- | 416.67 | -19.93 | -20.37 | -20.48 | -21.32 | -- | -- | -496,960.00 | -17,491.75 | -- | -- | 0.00 | -- | -97.72 | -- | -56.75 | -- | -17.18 | -- |
| 89bio Inc | 0.00 | -165.03m | 882.50m | 70.00 | -- | 1.67 | -- | -- | -2.01 | -2.01 | 0.00 | 5.36 | 0.00 | -- | -- | 0.00 | -30.80 | -45.50 | -32.70 | -49.31 | -- | -- | -- | -- | -- | -- | 0.0466 | -- | -- | -- | -39.37 | -- | -36.58 | -- |
| OPKO Health Inc | 799.60m | -252.43m | 906.09m | 3.93k | -- | 0.7233 | -- | 1.13 | -0.3427 | -0.3427 | 1.08 | 1.80 | 0.3859 | 7.53 | 6.87 | 203,461.30 | -12.18 | -7.14 | -13.58 | -8.14 | 32.63 | 34.42 | -31.56 | -13.83 | 1.58 | -4.96 | 0.2217 | -- | -14.01 | -2.70 | 42.49 | -- | -10.19 | -- |
Data as of May 17 2024. Currency figures normalised to Zentalis Pharmaceuticals Inc's reporting currency: US Dollar USD
84.10%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Matrix Capital Management Co. LPas of 31 Dec 2023 | 13.96m | 19.67% |
| Eventide Asset Management LLCas of 31 Dec 2023 | 11.56m | 16.29% |
| Fidelity Management & Research Co. LLCas of 31 Dec 2023 | 9.65m | 13.59% |
| SSgA Funds Management, Inc.as of 31 Dec 2023 | 4.42m | 6.23% |
| The Vanguard Group, Inc.as of 31 Mar 2024 | 4.24m | 5.98% |
| BlackRock Fund Advisorsas of 31 Mar 2024 | 4.23m | 5.96% |
| Citadel Advisors LLCas of 31 Dec 2023 | 3.61m | 5.09% |
| T. Rowe Price Associates, Inc. (Investment Management)as of 31 Dec 2023 | 2.85m | 4.01% |
| Capital Research & Management Co. (International Investors)as of 31 Dec 2023 | 2.82m | 3.97% |
| T. Rowe Price Investment Management, Inc.as of 31 Dec 2023 | 2.34m | 3.30% |
More ▼
Data from 31 Dec 2023 - 31 Mar 2024Source: FactSet Research Systems Inc.
